Cynthia Levy
University of Miami
Appearances
DateMay 8, 2023Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions…Presenter
University of Miami- DateMay 8, 2023Cholestatic liver diseases (CLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are a group of chronic liver disease which share some common clinical features present a variety of different complications and management decisions…
Presenters
University of MiamiYale University School of Medicine - DateMay 8, 2023SOCIETY: AASLD
Presenter
University of Miami 
DateMay 8, 2023SOCIETY: AASLDModerators
Columbia University Medical CenterUniversity of Miami
DateMay 20, 2024SOCIETY: AASLDModerators
University of MiamiUniversity of Calfornia Davis
DateMay 18, 2024ACUTE ON CHRONIC LIVER FAILURE AND THE MANAGEMENT OF CRITICALLY ILL PATIENTS WITH CIRRHOSIS + Q&AModerators
Columbia University Medical CenterUniversity of MiamiSpeakers
Baylor University Medical CenterVirginia Commonwealth Univ.- DateMay 18, 2024BACKGROUND: Seladelpar, a potent and selective PPAR-delta agonist, has anti-cholestatic and anti-pruritic activity in patients with primary biliary cholangitis (PBC)…
Presenter
University of Miami - DateMay 18, 2024INTRODUCTION: Obeticholic acid (OCA), a potent farnesoid X receptor agonist, is indicated as a second-line treatment for patients (pts) with primary biliary cholangitis (PBC) who have an inadequate response or intolerance to ursodeoxycholic acid…
Presenter
Speakers
DateMay 18, 2024ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)Moderators
Stanford UniversityDuke UniversitySpeakers
Michael E. DeBakey VAMCUniversity of Miami
